# Velavigo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/velavigo

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.velavigo.com
- Total disclosed funding: $50M
- Latest round: Angel (Nov 15, 2021)
- Investors on record: 5

## About

Founded in 2021 and based in Shanghai, China by Dr. Jing Li, who previously held senior R&D roles at Pfizer and Novartis. Velavigo specializes in the development of multispecific antibodies and antibody-drug conjugates (ADC) for oncology and autoimmune diseases, leveraging proprietary platforms to advance differentiated biologics with first-in-class (FIC) and best-in-class (BIC) potential. In July 2025, it closed a pre-series A+ funding round led by Shunwei Capital Partners.

The company develops multispecific antibodies and ADC therapies aimed at treating cancer and immune-related diseases.

The company generates revenue through research and development partnerships, technology licensing and milestone-based collaboration deals involving its pipeline of antibody-based therapies.

Velavigo will use the latest funding to initiate global clinical trials for its lead candidates, expand its clinical operations team and accelerate the development of innovative therapies for oncology and immune system disorders.

## Funding rounds

- Angel, Nov 15, 2021, $50M — HighLight Capital, Vertex Ventures China, MED-FINE Capital, Panacea Venture, Trinity Innovation Fund

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Angel
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Angel
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Angel
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Angel
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Angel